US20060166920 Dec 27, 2005 Jul 27, 2006 Regents Of The University Of Michigan Oligonucleotide based therapeutics
Riordan, et al (1991), Oligonucleotide Based Therapeutics, Nature 350 :442 443.Riordan, M.L., and Martin, J.C. (1991) Oligonucleotide-based therapeutics. Nature 350: 442-443.Riordan, et al. (1991), Oligonucleotide Based Therapeutics, Nature 350: 442 443....
Because of the advanced stages of oligonucleotide-based drug development, preclinical and clinical data are also presented by l... (展开全部) 我来说两句 短评 ··· 热门 / 最新 / 好友 还没人写过短评呢 我要写书评 Oligonucleotide Therapeutics的书评 ··· ( 全部0 条 ) 论坛 ··· ...
Research on oligonucleotide based therapeutics has intensified tremendously and several drugs have been approved in recent years. Future Use of Synthetic Nucleotides: Exploring DNA and RNA Vaccine Modalities Although not an oligonucleotide by strict definition, DNA- or RNA-based vaccine pro...
Oligonucleotide-based therapeutics are an emerging class of small drugs completely synthetic in origin, which do not integrate into the host genome, and have a defined duration of therapeutic activity after which effects recover to baseline. In addition, they offer a high degree of specificity for ...
Nucleic acid therapeuticsBerman CL, Cannon K, Cui Y et al (2014) Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics. Nucleic Acid Ther 24:291–301Berman CL, Cannon K, Cui Y, Kornbrust DJ, Lagrutta A, Sun SZ, et al. Recommendations for safety pharmacology...
The field of oligonucleotide (OGN)–based therapeutics has been growing dramatically in the past decade, providing innovative platforms to develop agents for the treatment of a wide variety of clinical conditions. OGN agents have unique physicochemical properties and pharmacokinetic/pharmacodynamic characteris...
To provide a snapshot of the current state of oligonucleotide therapeutics, the oligonucleotides currently under clinical development were categorized based on their mechanism of action and the type of vehicle used in their delivery (Fig. 10A and B). The distribution of mechanisms is somewhat consist...
The industry's most renowned event to accelerate oligo, peptide, and mRNA/vaccine therapeutics to market: Leading strategies for expediting R&D & improving CMC efficiency.
SMi Group Proudly Presents: Oligonucleotide Therapeutics and Delivery Conference Website: www.oligonucleotide.co.uk/gate2biowl On the way to maximising the potential of oligo-based medicine